image description
06 December 2016 | Reports

Paradigm Biopharma Research Report

Research Report on Paradigm Biopharmaceuticals.

The report contains:

  • Updated analyst commentary on Paradigm Biopharmaceuticals’ Pentosan Polysulfate Sodium (PPS) drug
  • Summary of Paradigm’s Hayfever & Bone Marrow Edema (BME or Bone Bruising) programs
  • Introduction of PPS as a treatment for Ross River Virus and Chikungunya Virus
  • Baker Young’s view on Paradigms’s share price drivers for CY2016
  • Valuation and Share Price target
  • 10 Reasons to Invest in Paradigm Biopharmaceuticals

Please enter your details below to get the report sent to your email address: